MedTrace Logo

Natural History of Patients With PH3 and a History of Stone Events

NCT04542590 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 7

Last updated 2024-12-02

No results posted yet for this study

Summary

This is a natural history study of adults, adolescents, and children (starting at birth) with genetically confirmed primary hyperoxaluria type 3 (PH3) who have a history of stone events during the last 3 years and/or the presence of pre existing stones detected by renal ultrasound at screening.

Conditions

  • Primary Hyperoxaluria Type 3

Sponsors & Collaborators

  • Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

    lead INDUSTRY

Principal Investigators

  • Verity Rawson · Dicerna, A Novo Nordisk Company

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-09
Primary Completion
2024-07-23
Completion
2024-07-23

Countries

  • United States
  • Canada
  • Germany
  • Poland
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04542590 on ClinicalTrials.gov